Science / March 26, 2023

Results of a 4-year Viltolarsen extension study of functional and safety outcomes

Results of a 4-Year Viltolarsen Extension Study of Functional and Safety Outcomes

Related

Press Release / January 23, 2025

FDA Grants Rare Pediatric Disease Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy

News / October 02, 2024

JAK1 Inhibition: Challenges and Opportunities

Press Release / May 27, 2024

NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study)